Title : Osimertinib plus selumetinib in EGFR-mutated, non-small cell lung cancer after progression on EGFR-TKIs: A Phase 1b, open-label, multicenter trial (TATTON Part B).

Pub. Date : 2022 May 26

PMID : 35617514






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Osimertinib plus selumetinib in EGFR-mutated, non-small cell lung cancer after progression on EGFR-TKIs: A Phase 1b, open-label, multicenter trial (TATTON Part B). AZD 6244 epidermal growth factor receptor Homo sapiens